Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inositec’s INS-3001 Reduces Cardiovascular Calcification
Details : INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.
Product Name : INS-3001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2020
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
Details : U.S. patent number covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.
Product Name : INS-3001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2020
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable